Journal
CLINICAL AND EXPERIMENTAL NEPHROLOGY
Volume 25, Issue 8, Pages 875-884Publisher
SPRINGER
DOI: 10.1007/s10157-021-02047-2
Keywords
Hemodialysis; IL-31; Itch; Nemolizumab; Uremic pruritus
Categories
Funding
- Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
Ask authors/readers for more resources
In patients with uremic pruritus, treatment with nemolizumab did not meet the primary efficacy endpoint, but some improvements were observed in the pruritus visual analog scale. Additionally, there were no significant differences in secondary efficacy parameters between treatment groups. Patients with higher serum IL-31 levels tended to have greater reductions in pruritus VAS following nemolizumab treatment.
Background The pathophysiology of uremic pruritus (UP), which is characterized by systemic and intractable itching, remains unclear. As interleukin (IL)-31 may be involved, we conducted a phase II, randomized, controlled study to evaluate nemolizumab (anti-IL-31 receptor A antibody) in Japanese hemodialysis patients with UP. Methods Patients were randomly assigned (1:1:1:1:1) to one of four double-blind groups (receiving a single subcutaneous injection of nemolizumab 0.125, 0.5, or 2.0 mg/kg, or placebo on Day 1) or an open-label reference group (receiving oral nalfurafine hydrochloride 2.5-5 mu g once daily for 12 weeks). The primary endpoint was the difference in the absolute change in pruritus visual analog scale (VAS) at Week 4 between placebo and each nemolizumab group. Results The primary efficacy endpoint was not met. The mean change from baseline with all three nemolizumab doses at Week 1, and with 0.5 mg/kg at Week 4, was greater than with placebo. Least square mean differences (95% confidence intervals) in the absolute changes between the placebo arm and each nemolizumab arm were - 2.4 (- 19.7, 14.9) for 0.125 mg/kg, - 8.7 (- 26.6, 9.2) for 0.5 mg/kg, and 0.4 (- 17.0, 17.8) for 2.0 mg/kg. Secondary efficacy parameters including the Shiratori severity score and 5-D itch score failed to show between-group differences. Patients with higher serum IL-31 levels at screening tended to have greater pruritus VAS reductions following nemolizumab treatment. Conclusions In this phase II study in patients with UP, the primary efficacy parameter was not met. Nemolizumab was generally well tolerated with no clinically significant safety concerns.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available